Retatrutide: what the trials show and the risks of "research" vials

Retatrutide is an experimental weight-loss medicine made by Eli Lilly. It is a once-weekly injection that acts on three hormone receptors at once: GIP and GLP-1, the two targets of tirzepatide (Mounjaro), plus the glucagon receptor. That third target is why it is often called a "triple agonist" or "triple G".

Interest jumped when the first large phase 3 trial, TRIUMPH-1, was published online in the New England Journal of Medicine on 29 September 2026; the print issue is dated 5 November 2026. At the same time, vials labelled retatrutide are being sold online as "research peptides". This guide covers what the trials show, what they do not, and why those vials are a different thing from the medicine studied in the trials.

The short answer: in an 80-week trial of 2,339 adults with obesity, the highest dose of retatrutide produced an average weight loss of 25.0%, against 3.9% with placebo. It has not yet been approved as a medicine, and its trial investigators still describe it as under clinical development. Anything sold as retatrutide today is outside the regulated supply chain, and no one can confirm what is in the vial.

What TRIUMPH-1 found

TRIUMPH-1 was a phase 3, randomised, double-blind trial. Adults with obesity who did not have diabetes were assigned to a weekly injection of retatrutide at 4 mg, 9 mg or 12 mg, or to placebo, for 80 weeks. The analysis counted everyone who was randomised, including people who stopped treatment.

• Average weight change: -17.6% at 4 mg, -23.7% at 9 mg and -25.0% at 12 mg, against -3.9% with placebo.
• Knee osteoarthritis (574 participants): pain scores on a 10-point scale fell by 3.2 to 3.6 points with retatrutide and by 1.9 points with placebo.
• Obstructive sleep apnoea (243 participants): breathing interruptions fell by 22.9 to 34.3 events an hour with retatrutide and by 9.9 with placebo.
• Side effects: the most common adverse events were gastrointestinal, such as nausea, diarrhoea and vomiting.

The trial was funded by Eli Lilly, and several authors are company employees. The published summary does not set out every safety result, so the full paper and regulators' reviews will matter more than headline weight-loss figures.

Who was in the trial

Participants had a BMI of 30 or more, or 27 or more with high blood pressure, abnormal blood fats, obstructive sleep apnoea or cardiovascular disease, and had tried at least once to lose weight by dieting. The trial registry lists who was excluded: people with diabetes, anyone who had had pancreatitis, people with a personal or family history of medullary thyroid cancer or the related MEN-2 syndrome, and anyone who had had or was planning weight-loss surgery. Those exclusions are one reason a prescriber's screening matters, and they are skipped entirely when someone buys a vial online.

Earlier trials

A 48-week phase 2 trial of 338 adults, published in 2023, found an average weight loss of 24.2% at 12 mg, against 2.1% with placebo. Gastrointestinal side effects were dose-related and mostly mild to moderate, and were reduced by starting at a lower dose. Heart rate rose with dose, peaked at 24 weeks and declined after that.

TRANSCEND-T2D-1, a 40-week phase 3 trial of 537 adults with type 2 diabetes published in The Lancet in June 2026, found HbA1c fell by 1.69% to 1.94% with retatrutide, against 0.81% with placebo, and body weight fell by 11.5% to 15.3%, against 2.6%. Between 2% and 5% of people on retatrutide stopped because of side effects, against none on placebo. No severe hypoglycaemia was reported.

What the trials do not tell you

• Whether it is better than tirzepatide or semaglutide. These trials compared retatrutide with placebo, not with other medicines.
• Long-term safety. The longest published trial ran for 80 weeks.
• Anything about unregulated vials. Every result above comes from a pharmaceutical-grade product given at set doses, with dose increases spread over weeks and medical monitoring throughout.
• Whether it suits people outside the trial groups, such as people with a lower BMI who want to lose a small amount of weight.

If you are thinking about a weight-loss medicine

• Ask a prescriber which authorised medicines suit your BMI, health conditions and other medicines.
• Ask how the dose will be increased and what to do about nausea, vomiting or constipation.
• Plan how you will keep eating enough protein and staying active while your appetite is low.
• Ask what happens when you stop, and how follow-up will work.

Why "research" vials are a different product

Online sellers typically offer retatrutide as a freeze-dried powder with a "for research use only" or "not for human consumption" label, often next to dosing calculators and bacteriostatic water for mixing. In an August 2026 warning letter to one such seller, the US Food and Drug Administration said that despite those labels, evidence on the company's website showed the products were intended for human use, and it treated retatrutide, tirzepatide and semaglutide vials as unapproved new drugs.

The practical risks are the same in every country. The dose in the vial is unknown, it may contain a different substance or none at all, it may be contaminated, and mixing and measuring a powder at home adds its own errors. The gastrointestinal side effects seen in the trials were dose-related, so an unknown dose is not a small problem.

UK regulatory status

The MHRA has been direct about this. In July 2026 it warned the public not to be tempted by the online hype around retatrutide, saying it has not been authorised for use in the UK, that anyone selling it is doing so illegally, and that there is no guarantee such products even contain retatrutide. Under the Human Medicines Regulations 2012, a product used to change how the body works is a medicine, and an unlicensed medicine cannot be sold or advertised to the public.

The GLP-1 medicines authorised in the UK for weight loss are semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda). The MHRA says they have only been shown to be safe and effective for people with a BMI of 27 or more, should be taken only as prescribed, and should be bought only with a prescription from a pharmacy registered with the General Pharmaceutical Council. Its advice is simple: if you are offered a GLP-1 medicine without a prescription, walk away.

Report a suspected side effect, or a suspected fake medicine, through the MHRA Yellow Card scheme. If you have severe stomach pain that does not go away, repeated vomiting, signs of dehydration or feel faint after an injection, call NHS 111, or call 999 in an emergency.

Supplements sold as "natural GLP-1" or "like retatrutide" are a separate issue. No food supplement has been shown to produce anything close to the weight loss seen in these trials. Our guide to supplements alongside GLP-1 medicines covers what nutrition support has evidence and what does not.

FAQ

Is retatrutide approved in the UK?

No. The MHRA says it has not been authorised for use in the UK and anyone selling it is doing so illegally.

How much weight did people lose on retatrutide?

In TRIUMPH-1, an average of 25.0% of body weight at the 12 mg dose over 80 weeks, against 3.9% with placebo, in adults with obesity without diabetes.

Is retatrutide better than Mounjaro?

That is not known. The published trials compared retatrutide with placebo, not with tirzepatide.

Can I join a retatrutide trial?

Trials are listed on public registers such as ClinicalTrials.gov. Your GP or obesity service can tell you whether a study near you is recruiting.

Are "research peptide" vials the same as the trial drug?

No. They are not made or checked under medicines rules, so their content and dose are unknown.